Companies: 10,795·Total market cap: $144.5T

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics

MLTXNASDAQHealthcare● Active

$18.00

+$0.10(+0.56%)

Market Cap$1.3B

P/E Ratio—

52W High$62.75

52W Low$5.95

Avg Volume997K

Open$18.24

Beta1.04

Net Income Financials Revenue

MoonLake Immunotherapeutics (MLTX) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

MLTX · net income · updated Jun 9, 2026

Core profitability metrics

MLTX · net income · margin · TTM · CAGR

Net income was −$227.3M for FY2025 (fiscal year ending 2025-12-31), down 91.1% year-over-year. Net profit margin was —.

FY2025 Net Income−$227.3M▼ -91.1% YoY

Trailing 12M (TTM)−$257.1Mtrailing 4 quarters sum

Net Profit Margin——

YoY Change-91.1%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · MLTX net income history · MLTX profit margin

Annual net income data

MLTX · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$227.3M▼ 91.1%—$0

FY2024Loss−$118.9M▼ 230.3%—$0

FY2023Loss−$36.0M▲ +27.9%—$0

FY2022Loss−$50.0M▲ +6.8%—$0

FY2021Loss−$53.6M▼ 58954.2%—$0

Net income vs peers (Healthcare)

MLTX vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

MoonLake ImmunotherapeuticsYOU

MLTX

−$227.3M-91.1%—

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

MoonLake Immunotherapeutics (MLTX) reported net income of −$227.3M for FY2025 (fiscal year ending 2025-12-31), down 91.1% year-over-year. The net profit margin was — — meaning the company kept $— of every dollar of revenue as profit.

MoonLake Immunotherapeutics has not yet achieved annual profitability based on available data (6 fiscal years). The company has reported net losses across all available periods.

MoonLake Immunotherapeutics's net profit margin was — for FY2025, based on the latest annual results.

Investors sometimes search for "MoonLake Immunotherapeutics net worth" — the company's market capitalization is a separate figure from MLTX net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

MLTX net income · 4 questions

MoonLake Immunotherapeutics is not currently profitable on an annual basis. The company reported a net loss of $227.3M for FY2025.

is MLTX profitabledoes MLTX make a profitMLTX profitabilityMLTX profitable company

▸ Source: FMP /income-statement · GAAP · MoonLake Immunotherapeutics · MoonLake Immunotherapeutics SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026